News | September 14, 2012

IBA Molecular Introduces Centers for Innovation

September 14, 2012 — IBA Molecular North America Inc., a manufacturer and distributor of PET imaging tracers, has announced the introduction of its Centers for Innovation, two unique facilities designed for advanced radiopharmaceutical contract development and manufacturing. The centers are located in Totowa and Somerset, N.J.  Complementing these sites are IBA Molecular's production capabilities for isotopes such as I-124, F-18, Zr-89 and in the future, Cu-64 and Y-86. The centers are expected to play an important role in the development of a new generation of disease-specific tracers and companion theragnostics.

The primary site is a state-of-the-art radiopharmaceutical facility in Totowa, N.J. This fully equipped 8,500-square-foot research and development center is staffed by a team of accomplished professionals, including radiochemists, nuclear pharmacists, QC chemists and cyclotron engineers. The staff has expertise in radio-labeling, product development and industrialization of new tracers, technology transfer and GMP production of doses for clinical trials.  These attributes make the site an ideal destination for collaborative projects. With both large (mAbs, proteins, etc.) and small molecule radio-labeling expertise, the center can develop processes to support almost any new tracer, including those that utilize isotopes such as F-18, I-124 and Zr-89.  All of these endeavors are geared toward supporting human clinical trials of novel tracers.

These GMP-validated sites provide a broad range of capabilities, including:

  • Compounding of I-124 capsules for clinical use
  • Producing the highest purity I-124 available under a DMF for this radioisotope
  • Production of novel tracers integral to preclinical translational research
  • Scalable infrastructure and investigational products for all phases of clinical studies
  • Production of novel tracers integral to hybrid-probe development
  • A supporting resource or "think-tank" for development and industrialization
  • Scalable infrastructure capable of supporting solid targetry for research isotope production including Cu-64, Y-86 and other isotopes


"The molecular imaging industry needs an accelerant to drive innovation and new products. Our specialized knowledge and outstanding facilities in radiopharmaceutical development and manufacturing are at the disposal of our partners and will undoubtedly assist in bringing new products to the market faster," said Lee Karras, president of IBA Molecular North America Inc. "These Centers for Innovation will provide researchers, pharma and biotech companies with access to our unmatched expertise in small and large molecules, as well as our proven track record with the development of novel tracers.  Standing alongside these centers is IBA Molecular's global commercial network of nuclear pharmacies, which will be paramount to the successful launch of any new, commercialized tracer."

IBA Molecular has development and manufacturing partnerships with a number of pharmaceutical firms, including Wilex, Aposense and Piramal Imaging, as well as ongoing research collaborations with noted medical institutions throughout the U.S. and Europe.

For more information: www.iba-molecular.com

Related Content

NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve
Improving Molecular Imaging Using a Deep Learning Approach
News | Nuclear Imaging | March 21, 2019
Generating comprehensive molecular images of organs and tumors in living organisms can be performed at ultra-fast speed...
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...
Siemens Healthineers Announces First U.S. Install of Biograph Vision PET/CT
News | PET-CT | March 06, 2019
Siemens Healthineers’ new Biograph Vision positron emission tomography/computed tomography (PET/CT) system has been...
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...
FDA Clears United Imaging Healthcare uExplorer Total-Body Scanner
Technology | PET-CT | January 23, 2019
January 23, 2019 — United Imaging Healthcare (United Imaging) announced U.S.
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...